| scholarly article | Q13442814 |
| P356 | DOI | 10.2967/JNUMED.110.086645 |
| P698 | PubMed publication ID | 21622893 |
| P50 | author | Eugen Trinka | Q66943403 |
| P2093 | author name string | Markus Hutterer | |
| Andreas H Jacobs | |||
| Daniel Putzer | |||
| Irene J Virgolini | |||
| Martha Nowosielski | |||
| Dietmar Waitz | |||
| Guenther Stockhammer | |||
| Thaddäus Gotwald | |||
| Armin Muigg | |||
| Herwig Kostron | |||
| Gerd Tinkhauser | |||
| Wolfgang Staffen | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | angiogenesis inhibitor | Q574834 |
| P304 | page(s) | 856-864 | |
| P577 | publication date | 2011-06-01 | |
| P1433 | published in | The Journal of Nuclear Medicine | Q7743608 |
| P1476 | title | O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma. | |
| P478 | volume | 52 |
| Q47560758 | 18F-DOPA uptake parameters in glioma: effects of patients' characteristics and prior treatment history |
| Q52801683 | 18F-FDOPA PET/MRI for monitoring early response to bevacizumab in children with recurrent brain tumors. |
| Q38403271 | 18F-FET PET prior to recurrent high-grade glioma re-irradiation-additional prognostic value of dynamic time-to-peak analysis and early static summation images? |
| Q35094941 | 18F-FET microPET and microMRI for anti-VEGF and anti-PlGF response assessment in an orthotopic murine model of human glioblastoma |
| Q36179310 | 3'-deoxy-3'-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab |
| Q36339461 | Advances in neuro-oncology imaging. |
| Q42234940 | Amino Acid PET - An Imaging Option to Identify Treatment Response, Posttherapeutic Effects, and Tumor Recurrence? |
| Q38691946 | Amino acid PET and MR perfusion imaging in brain tumours. |
| Q36374577 | An Update on the Approach to the Imaging of Brain Tumors |
| Q35156126 | An intra-individual comparison of MRI, [18F]-FET and [18F]-FLT PET in patients with high-grade gliomas |
| Q38635290 | Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance? |
| Q55457499 | Biological tumour volumes of gliomas in early and standard 20-40 min 18F-FET PET images differ according to IDH mutation status. |
| Q24605136 | Brain tumors |
| Q36218548 | Change in 18F-Fluoromisonidazole PET Is an Early Predictor of the Prognosis in the Patients with Recurrent High-Grade Glioma Receiving Bevacizumab Treatment |
| Q39817583 | Characterization of the serum metabolome following radiation treatment in patients with high-grade gliomas |
| Q41594601 | Clinical PET/MRI in neurooncology: opportunities and challenges from a single-institution perspective |
| Q34348544 | Comparison of amino acid positron emission tomographic radiotracers for molecular imaging of primary and metastatic brain tumors |
| Q90292683 | Cost-Effectiveness of [18F] Fluoroethyl-L-Tyrosine for Temozolomide Therapy Assessment in Patients With Glioblastoma |
| Q90663490 | Current Landscape and Emerging Fields of PET Imaging in Patients with Brain Tumors |
| Q26853308 | Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients |
| Q97542753 | Current status of PET imaging in neuro-oncology |
| Q36500372 | Detection of glioblastoma response to temozolomide combined with bevacizumab based on μMRI and μPET imaging reveals [18F]-fluoro-L-thymidine as an early and robust predictive marker for treatment efficacy |
| Q48451808 | Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET. |
| Q41904258 | Discrepant MR and [(18)F]Fluoroethyl-L-Tyrosine PET Imaging Findings in a Patient with Bevacizumab Failure |
| Q55456668 | Early treatment response evaluation using FET PET compared to MRI in glioblastoma patients at first progression treated with bevacizumab plus lomustine. |
| Q35914501 | FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan |
| Q38474606 | Follow-Up Imaging: Molecular Imaging is Likely Best as a Single Modality, but Multimodality Imaging is the Future |
| Q35679377 | From the clinician's point of view - What is the status quo of positron emission tomography in patients with brain tumors? |
| Q53109990 | Glioma FMISO PET/MR Imaging Concurrent with Antiangiogenic Therapy: Molecular Imaging as a Clinical Tool in the Burgeoning Era of Personalized Medicine. |
| Q54973707 | Imaging in neuro-oncology. |
| Q36383638 | Imaging of amino acid transport in brain tumours: Positron emission tomography with O-(2-[(18)F]fluoroethyl)-L-tyrosine (FET). |
| Q64924335 | Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0. |
| Q35895174 | Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma. |
| Q48588122 | Letter to the Editor: "The role of imaging in the management of progressive glioblastoma. A systematic review and evidence-based clinical practice guideline" [J Neurooncol 2014; 118:435-460]. |
| Q55462196 | MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET? |
| Q89688127 | Metabolic Tumor Volume Response Assessment Using (11)C-Methionine Positron Emission Tomography Identifies Glioblastoma Tumor Subregions That Predict Progression Better Than Baseline or Anatomic Magnetic Resonance Imaging Alone |
| Q38822001 | Multimodal imaging based on MRI and PET reveals [(18)F]FLT PET as a specific and early indicator of treatment efficacy in a preclinical model of recurrent glioblastoma. |
| Q36029393 | Overexpression of L-Type Amino Acid Transporter 1 (LAT1) and 2 (LAT2): Novel Markers of Neuroendocrine Tumors. |
| Q39498230 | PET/MRI in cancer patients: first experiences and vision from Copenhagen |
| Q48158155 | Positron emission tomography imaging in gliomas: applications in clinical diagnosis, for assessment of prognosis and of treatment effects, and for detection of recurrences |
| Q52663401 | Potential use of prostate specific membrane antigen (PSMA) for detecting the tumor neovasculature of brain tumors by PET imaging with 89Zr-Df-IAB2M anti-PSMA minibody. |
| Q89448201 | Prognostic value of 18F-FET PET/CT in newly diagnosed WHO 2016 high-grade glioma |
| Q90746646 | Recurrent glioblastoma versus late posttreatment changes: diagnostic accuracy of O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography (18F-FET PET) |
| Q40232491 | Reproducibility of O-(2-(18)F-fluoroethyl)-L-tyrosine uptake kinetics in brain tumors and influence of corticoid therapy: an experimental study in rat gliomas. |
| Q38815396 | Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. |
| Q44461998 | Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI. |
| Q52950126 | Response assessment of bevacizumab therapy in GBM with integrated 11C-MET-PET/MRI: a feasibility study. |
| Q31156299 | The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy |
| Q33740417 | The use of longitudinal 18F-FET MicroPET imaging to evaluate response to irinotecan in orthotopic human glioblastoma multiforme xenografts |
| Q33740196 | Towards standardization of 18F-FET PET imaging: do we need a consistent method of background activity assessment? |
| Q33838502 | Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy |
| Q48947048 | Usefulness of PET Imaging to Guide Treatment Options in Gliomas. |
| Q97543249 | Value of [18F]-FDG positron emission tomography in patients with recurrent glioblastoma receiving bevacizumab |
| Q35760788 | [(18)F]-fluoro-L-thymidine PET and advanced MRI for preoperative grading of gliomas. |
| Q30442436 | [18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma |
| Q60924133 | [18F]FET PET is a useful tool for treatment evaluation and prognosis prediction of anti-angiogenic drug in an orthotopic glioblastoma mouse model |
| Q35453822 | ²³Na-MRI of recurrent glioblastoma multiforme after intraoperative radiotherapy: technical note |
Search more.